1 / 54

KT Trials Must Overcome Both Poor Practitioner and Patient Performance

KT Trials Must Overcome Both Poor Practitioner and Patient Performance. ...many unanswered questions and a plea for collaboration, innovation and research. Brian Haynes. Objectives. To review some problems of practitioner and patient adherence

hgoss
Download Presentation

KT Trials Must Overcome Both Poor Practitioner and Patient Performance

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. KT Trials Must Overcome Both Poor Practitioner and Patient Performance ...many unanswered questions and a plea for collaboration, innovation and research Brian Haynes

  2. Objectives • To review some problems of practitioner and patient adherence • To assess the “state of the science” in overcoming these problems • To invite transdisciplinary researchers to “gang up” on these problems

  3. For every complex problem... ...there is a simple solution... ...and it is wrong. C. S. Snow

  4. How many of you are doing/have done… …research in which both practitioner and patient adherence are targeted?

  5. Knowledge Translation Research KT Type 1 KTType 2 Based on Hulley et al. Designing Clinical Research, 2007, p 23

  6. E X KT2 = ROI RO1 grants Efficacy Knowledge Translation (type 2) Return on Investment Real Outcomes of Importance

  7. E = Efficacy... …effects of health care interventions under relatively optimal circumstances. (Can this work?)

  8. KT2 = Knowledge Translation 2 E X KT2 = ROI …the organization, retrieval, appraisal, refinement, dissemination, and timely application of knowledge (eg, important new knowledge from health research)

  9. E X KT2 = ROI Clinician adherence ~ 50% Where: E is typically ≤ 0.25 KT2 is typically ≤ 0.25 Patient adherence ~50% So: ROI is typically... .25 X .25 = .06

  10. E X KT2 = ROI Clinician adherence 50% Where: E is typically ≤ 0.25 KT2 is typically ≤ 0.25 So: ROI is typically... Patient adherence 50% 75% .09 .25 X .25 = .06 .38

  11. E X KT2 = ROI Where: E is typically ≤ 0.25 KT2 is typically ≤ 0.25 Clinician adherence 50%75% Clinician adherence 50%75% So: ROI is typically... Patient adherence 50% 75% .14 .25 X .25 = .06 .56

  12. Clinician Adherence

  13. When I was a graduate student… In trials of antihypertensive therapy, some of the physicians didn’t know what they were doing……only 49% of patients in the community were treated…among the prescriptions for ‘treated’ patients were Valium and Phenobarbital

  14. In all, 73% of microalbuminuric patients were not on ACE-I/ARB. • Hypertensive type II diabetic patients were often left untreated and only a minority of those treated were optimally controlled.

  15. Typical implementation rates for stroke care < 50%

  16. The Slippery Slope 100% r = -0.54 p<0.001 . .. . . .... . doctors’ knowledge of current best care ... ... ... 50% ... .. .... .... 0% years since graduation Evans CE, et al CMAJ 1984

  17. Typical time to regular implementation of innovations 17 to 20 years

  18. Corticosteroids for threatened preterm delivery* *Wirtschafter et al. 2006 California increased use of antenatal corticosteroids from 76% to 86% over a 3 year period with a statewide QI cycle.

  19. EPOC: Cochrane Review Group on Effective Practice and Organization of Care Reviews of interventions to assist professionals to improve the quality of care they provide.

  20. Results from an Overview of Previous Systematic Reviews of Professional Behavior Change Strategies* Generally ineffective Dissemination of printed educational materials Didactic educational session Mixed effects Audit and feedback Local opinion leaders Generally effective Reminders Educational outreach Multifaceted interventions Grimshaw et al, J Contin Educ Hlth Professions 2004. least cost & most offered mean absolute effect 10%

  21. Ways to improve performance preferred by docs vs tested & work journal reading audit & feedback scientific sessions incentives informal consults preceptorships rounds local opinion leaders med school events educational outreach libraries reminders

  22. Cost-effectiveness of warfarin* Warfarin for atrial fibrillation • $25 saved per stroke averted *Gustafsson C, et al. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ. 1992;305:1457-60.

  23. What proportion of patients with atrial fibrillation do not receive anticoagulants? 48% Niska R, Han B. Anticoagulation for patients with atrial fibrillation in ambulatory care settings. J Am Board Fam Med. 2009;22:299-306

  24. Physician and patient mean bleeding thresholds for warfarin* • Baseline risk of 12 strokes and 3 major bleeds in 100 patients over 2 years • Given warfarin would decrease the risk of stroke to 4 in 100 patients we then determined the maximum number of excess bleeds that participants were willing to accept *P. J. Devereaux et al, BMJ 2001; 323:1218-22

  25. * P. J. Devereaux et al, BMJ 2001; 323:1218-22

  26. * P. J. Devereaux et al, BMJ 2001; 323:1218-22

  27. Detection Doctors’ judgements of their patients’ adherence: • sensitivity 10% • specificity 88% Gilbert et al, CMAJ 1980

  28. Patient Adherence

  29. Detection Asking patients about their compliance: • sensitivity 55% • specificity 95% Stephenson et al, JAMA 1993

  30. Patient adherence - definition... ...extent to which a person's behavior (in terms of taking medication, following a diet, modifying habits or attending clinics) coincides with medical or health advice = patient compliance ≠ concordance (…with agreed recommendations, WHO)

  31. The age-old adherence dilemma... “There’s many a slip twixt the cup and the lip.”

  32. How frequent is nonadherence? TASKNON- ADHERENCE RATES* Screening in community 35%-90% Referral from screening 50%-65% Staying in care 31%-66% Follow-up appointments 16%-84% Medications 31%-58% Weight loss 29%-100% Smoking cessation 71%-96% * Sackett and Snow, 1979

  33. The new adherence dilemma... There are many more efficacious, self-administered treatments now Our ability to help patients follow their treatments has not kept pace Thus, the gap between how healthy people could be and how healthy they are has widened a lot

  34. Adherence to beneficial therapy saves lives adherers non-adherers Simpson et al, BMJ, June 2006

  35. How important is adherence “healthy adherer effect” Simpson et al, BMJ, June 2006

  36. Adherence to bad therapy is lethal… Simpson et al, BMJ, June 2006

  37. Interventions to Improve Compliance with Prescribed Medications: A Systematic Review Brian Haynes Elizabeth Ackloo Navdeep Sahota Aqeel Degani Cochrane Database of Systematic Reviews , April 2008

  38. Criteria for Selection • Types of Studies • Randomized controlled trials • Types of Participants • Patients who are prescribed medications for medical (including psychiatric) disorders • Types of Interventions • Any intervention intended to improve patients’ adherence to self-administered prescribed medications

  39. Overall findings * No major clinical outcomes measured/affected

  40. Components of ‘successful interventions’ for chronic care* *None successful on own.

  41. The intervention consisted of meetings in a group setting with the parents. The sessions took place in the afternoon and lasted about 1.5 hours. Shortly after the children were diagnosed as an asthmatic, three meetings (one every week for three weeks) took place and a followup meeting took place 6 months later. Three paediatricians, three nurses and two psychologists were involved in these sessions: one nurse was present on all occasions, and the doctors and psychologists on three each. The goal of all the meetings was to reach the parents' "main worry" and, apart from teaching about asthma, the following key question was asked: "What is asthma to you?" The use of dialogue and peer education, whereby the group was encouraged to share personal experiences was emphasized. The intervention group received basic education about asthma and its treatment, including how to use the Nebunette, and information on environmental control at the first visit to the clinic. They received a written treatment plan where the principle was high dose (0.2mg of budesonide for 3 days) initially and then, in association with URTI, stepping down the therapy to the lowest possible dose according to the status of the child. The treatment was stopped if the child had no asthma for 6 months.

  42. Problems with the research… • Many studies too small to detect a benefit (need about 50 per group to detect a 25% absolute difference in adherence with 80% power)

  43. Problems with the research... The research is fragmented weak noncumulative unimaginative impractical often atheoretical or hypotheoretical Most research is done by “amateurs”

  44. Knowledge of hypertension bore no relationship to compliance either at the beginning of the study (r = -0.03) or at 6 months (r=0.08)Those who mastered the knowledge fared no better than those who did not. …socially unacceptable! (but highly reproducible…)

  45. Problems with the research… • Measures of adherence are imprecise • Measures of outcomes are intermediate at best (eg blood pressure; viral load) • Follow-up too short/not repeated post-intervention

  46. Conclusions • Low adherence is a major health problem (and can be fatal) • Research documents the limited effects of interventions to date • Interventions that have some effect are typically complex and “labour intensive” (= expensive) • More and better research is needed!

  47. What to do: Priorities for advancing adherence (international panel)* • Simple, feasible interventions (for *both* clinicians and patients) • Improved theory/development through conjoint efforts of medical, pharma, social and ‘technical’ scientists * Van Dulmen et al. BMC Health Services Research 2008, 8:47

  48. What to do: Priorities for advancing adherence (international panel)* • Involve patient groups • Focus efforts on non-adherent patients • Focus theory development on improving adherence (rather than explaining it) * Van Dulmen et al. BMC Health Services Research 2008, 8:47

  49. We need to innovate… across disciplines along the path of care across diseases

More Related